<DOC>
	<DOCNO>NCT02844361</DOCNO>
	<brief_summary>The purpose study evaluate whether autologous stem cell transplantation improve survival patient high-risk Waldenström macroglobulinemia , compare conventional chemotherapy .</brief_summary>
	<brief_title>Comparison ASCT Conventional Chemotherapy High Risk Waldenström Macroglobulinemia</brief_title>
	<detailed_description>WM patient partial response introduction chemotherapy recommend adopt autologous stem cell transplantation receive conventional chemotherapy ( dependent patient 's choice ) . After transplantation conventional chemotherapy , maintenance therapy rituximab thalidomide plus prednisone give less two year .</detailed_description>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<criteria>1 . 70 year &gt; =Aged &gt; =18 year 2. diagnose highrisk LPL/WM accord ISSWM criterion 3. untreated mild treat without standard regimen 4. suitable ASCT 5. lifeexpectancy 3 month . 1. diagnosed malignancy outside BNHL within one year ( include active center neural system lymphoma ) 2. transform lymphoma 3. liver renal function lesion unrelated lymphoma 4. serious complication uncontrolled diabetes , gastric ulcer serious angiocardiopathy determine physician 5 . HIV positive active HBV infection uncontrolled systematic infection 6. clinical central nervous dysfunction 7. serious surgery within 30 day 8. pregnancy baby nursing period uncontracepted childbearing period woman ; 9. allergy trail drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>high-risk</keyword>
	<keyword>ASCT</keyword>
</DOC>